PDCD1 and renal cell carcinoma: Targeting the programmed cell death-1 protein (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), ICIs have truly revolutionized metastatic RCC management [8], and their use in different combination strategies has become a novel standard of care in this patient population [9].